JRNYS Review
Semaglutide GLP-1 weight-loss telehealth · Independently scored 5.9/10
Best for: seeing what it charges before you answer any medical questions
JRNYS's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the plan
Medication
Charged on top
Clinician visits
In the price
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
What you pay for coaching sets the membership: $89 to $169 per month. On top of that, JRNYS states that a member holding commercial insurance should find the GLP-1 itself capped near $25/month once any deductible clears. Self-pay exists, priced only after a provider consult. The drugs are all branded, semaglutide as Ozempic or Wegovy, tirzepatide as Mounjaro or Zepbound, plus dulaglutide and liraglutide as Saxenda, wrapped in 1-on-1 coaching. Dr. Henry Legere is CMO. The company notes the indication for these drugs is diabetes and that weight loss is an off-label use.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to JRNYS
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
JRNYS at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Sema, tirz, liraglutide
- Starting price
- $89/mo
- What's included
- Consult
- FDA status
- No FDA warning letter on record
How JRNYS scores
Six columns, each one computed from something JRNYS has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10The figures published here are not comparable monthly cash prices for the medication — an insured copay, a per-vial rate, a membership fee or a starting-dose teaser. Capped rather than scored against the register.
Effectiveness25%
9.0/10Dispenses semaglutide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
6.5/10does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
2.5/10The price covers consult.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on JRNYS
Last checked August 2026- Re-read the price on file across 2 dose or plan tiers
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with JRNYS involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1JRNYS publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3JRNYS does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering consult.
- No comparable monthly cash price for the medication is on record — either nothing is published, or what is published is a fee, an insured copay or a per-vial rate rather than a monthly cost.
- No state list is published, so whether JRNYS serves your state cannot be confirmed from its site.
GLP-1 medications JRNYS offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Check the price yourself before you pay
Every figure here was read off JRNYS's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers consult
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- Billed separately from the monthly figure: medication
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
What JRNYS charges
JRNYS does not publish a standing monthly price. That is a choice, and it means you cannot compare it against anything until you have gone through an intake and been quoted. When you get that quote, ask specifically for the ongoing monthly figure and what it includes — not the first-month rate, and not a program total divided by its length.
What JRNYS dispenses
JRNYS prescribes semaglutide (approved as Wegovy and Ozempic). Between them these are among the best-evidenced options in this class. These are FDA-approved brand-name products rather than compounded preparations, which is the more expensive route and the one where what is in the vial has been reviewed.
What we could verify
On the record: coaching is included rather than sold on top. We searched the federal warning-letter record for this operator and came back with nothing. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You need to compare prices before committing time to an intake — there is no published figure to compare.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- you want coaching bundled rather than metered
Our read
We cannot tell you whether JRNYS is priced well, because it does not say. That is not automatically disqualifying — plenty of legitimate operators quote after intake — but it does mean the comparison has to happen after you have spent the time, which is the wrong order for the buyer. CoreAge Rx is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
JRNYS's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay JRNYS
Check today's price, then book the free consultation.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this JRNYS review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
See JRNYS's current pricing
The free consultation is where you learn whether you qualify, and what it costs today.